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ABSTRACT
Background: The US Food and Drug Administration (FDA) is in charge of regulating medical
devices and one key power the FDA has to ensure safety and effectiveness of these devices is
risk reclassification. One example of this regulatory power is the 515 Program Initiative, where
the FDA was tasked with reclassifying preamendment devices that had never undergone initial
rigorous review before entering the market.
Objective: The objective of this thesis project is to characterize the device types reassessed
under this program and determine what characteristics the FDA heavily considers when making
a risk classification determination.
Methodology: Data was collected on all 23 device types reviewed through this initiative on a
variety of characteristics: therapeutic area, implantable, life-sustaining, reclassification
mechanism, prior 510(k)s, devices out after reclassification, advisory committee decisions,
recalls, and public comments. Additionally, Fisher exact tests were conducted to assess whether
these characteristics were associated with final risk classification decisions.
Results: Of the 23 classification rules and orders, 15 called for downclassifications from Class
III to Class II or Class I device types and 8 called for devices to remain Class III. Most device
types characteristics were not significantly associated with the downclassification decision,
except for advisory committee decisions (P = 0.000) and reclassification mechanism (P = 0.000).
Conclusion: The FDA should consider these key regulatory processes when making
reclassification decisions. These findings suggest that the FDA prioritizes certain key players,
such as experts within advisory committees, during their decision-making process and that
regulatory burdens could both help and hinder the FDA’s mission to ensure safety and
effectiveness.
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INTRODUCTION
One power under the FDA’s authority in order to protect the public from unsafe medical
devices is reclassification of medical devices into new risk categories if they pose more or less
risk, after these devices have been on the market for some time. One example of this is the 515
Program Initiative, where the FDA was tasked with re-evaluating preamendment devices and
their current risk category. But there are concerns over whether the FDA may be
downclassifying devices that still pose high levels of risk, raising additional safety concerns. To
understand the relative importance of the 515 Program Initiative, I examined key factors that go
into the FDA’s decision-making process with regards to medical device regulation as a whole.
Medical devices in the US have been regulated since the 1938 Federal Food, Drug, and
Cosmetic Act but they were originally regulated under an expanded definition of drugs, rather
than a device-specific statute. Despite their inclusion under the 1962 Kefauver-Harris
amendments, which first required the use of clinical trials during pre-market review, devices
were not required to undergo any clinical trials prior to approval. It was not until 1976, when
Congress passed the Medical Device Amendments (MDA), where medical devices were required
to undergo a more rigorous pre-market review process.i
As established by the MDA, medical devices are now regulated by their risk
classification. There are three risk classifications: Class I, low risk; Class II, moderate risk; and
Class III, high risk. Only Class III medical devices undergo pre-market approval (PMA), which
requires a “reasonable assurance of device safety and effectiveness” involving at least one
pivotal clinical trial. Class I and II medical devices are either required to meet general controls or
receive clearance through the 510(k) pathway. The 510(k) pathway requires that the new device
is “substantially equivalent” to another predicate device(s), which does not require clinical data,
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unless the FDA asks for it, which the FDA rarely does.ii “Substantial equivalence” is based on
similarity to predicates, which are devices that have already been cleared by the FDA, even if
these predicate devices have been recalled because of ineffectiveness or safety concerns.
Although the 510(k) pathway was intended to regulate only moderate-risk devices, this pathway
was temporarily used for preamendment devices that were initially regulated as Class III, with
the FDA intending to downclassify them or keep the Class III classification and require PMA
applications.
As another safeguard to protect patient safety, the FDA has the authority to request PostApproval Studies or 522 postmarket surveillance studies. Post-approval studies require the same
clinical rigor as PMA studies but occur after approval and can be a condition of devices
approved through the PMA pathway.iii Similarly, the FDA can require a manufacturer to conduct
522 postmarket surveillance studies of a Class II or III device, based on certain risk and safety
criteria.iv Both are used to help ensure the safety of riskier medical devices, but not only does the
FDA rarely require them but also many of these studies are not completed.v
Since 1976, all new devices have been risk classified and reviewed accordingly. But, as
there were many devices on the market prior to the creation of the MDA, Congress needed to
determine how to reassess those devices, referred to as preamendment devices. These
preamendment device types were automatically given a Class III risk designation until further
FDA review to assess if these devices warranted a Class III designation or could be
downclassified. But despite the need to review these devices, it was a lower priority for the FDA
in practice as the FDA still had many preamendment devices to assess.
To facilitate this process of reanalyzing these preamendment devices, as well as to
improve the reclassification process to more effectively regulate new devices, the FDA kicked
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off the 515 Program Initiative, named after the section of the Food, Drug, and Cosmetic Act
(FD&C Act) it draws its power from, which used the agency’s rulemaking power to reclassify
devices. But in 2012, as part of the Food and Drug Administration Safety and Innovation Act
(FDASIA) amended Section 515 of FD&C Act, which originally required the final
administrative action to use rulemaking and now has altered it to utilize an administrative order
process. More specifically, under FDASIA changes to Section 515, the FDA used a 5-step
reclassification process to finalize classification for the devices: (1) review existing scientific
information to assess risks and benefits, (2) convene expert advisory panel, (3) issue proposed
risk classification, (4) review public comments, and (5) issue final risk classification. vi
Additionally, to change the classification of the device, the proposed new class needed to have
sufficient regulatory controls to provide reasonable assurance of safety and effectiveness for its
intended use. As of 2009, 26 medical device regulations still required action. Under the 515
Program Initiative, by the end of 2019, the FDA had finalized their classifications.vii
These steps to reclassification are critical because they serve as ways to ensure the FDA
is considering the safety and effectiveness considerations from all angles. The expert advisory
panel ensures the FDA is in line with recent medical literature and practice of these devices.
Similarly, the public comments serve as the FDA’s main mechanism to listen to patients and
other stakeholders but this could be interesting to evaluate and determine if the FDA listens to
specific groups more heavily.
All in all, the 515 Program Initiative is important because it speaks to larger issues within
the FDA, e.g., how it goes about reclassifications, regulatory burdens, and how these actions
connect to the FDA’s greater mission of ensuring patient safety. Most importantly, this program
speaks to the FDA’s authority and their use of it to compel rigorous evaluation and evidence to
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inform practices (both during the premarket and postmarket phases). The results from this
program play a large role in whether future devices could be more or less safe when introduced
to the market and how this could impact patients. The program is not only representative of
many of the FDA’s internal activities but it is also the key to understanding the motivations of
the FDA with regards to their broader decision-making processes and how well it is carrying out
its patient-oriented mission.
The objectives of this thesis are to assess the 515 Program Initiative and characterize the
downclassifications of preamendment devices. Moreover, this assessment aims to elucidate the
process of FDA-decision making, by analyzing what factors the FDA is considering when
deciding whether to downclassify a device. I suspect that a few factors play a key role in whether
the FDA decides to downclassify a specific device.

METHODOLOGY
I constructed the sample of device types from all remaining preamendment device types
that needed to be reevaluated under the 515 program and were therapeutic devices (not
diagnostic), which were pulled directly from the FDA website as making this information
publicly accessible is explicitly required in the FDASIA. Ultimately, 23 devices were evaluated
for this study.
Downclassifications
For all devices undergoing reevaluation, the FDA could choose to keep them as Class III
devices, downclassify to Class II or Class I, or split reclassify them, where the original device
type is downclassified but the FDA creates a new device type as an offshoot of the original that
is designated as Class III. For the purposes of this paper and its analysis, devices that were splitreclassified will be considered as “downclassified” as well.
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Device Type Base Characteristics
Using information from the publicly accessible FDA “Product Classification” database, I
was able to classify each device type in the sample by the following characteristics: division of
care / therapeutic area, implantable designation (yes / no), life-sustaining designation (yes / no),
and whether device type was reclassified via rule or order. A few other characteristics were also
evaluated. Pulling from the Post-Approval Studies (PAS) Database, I searched through this
database to determine whether any of these device types had PAS/522 requirements.
Additionally, to assess whether the device types had devices approved through the 510(k)
pathway and had devices out after the reclassification decision, I used the premarket notifications
(510(k)s) database and premarket approvals (PMA) database. Advisory committee history was
reviewed through a reading of the final rules and orders.
Recall History
In order to characterize each device type’s recall history, I used the “Recalls of Medical
Devices” database. Using each device type’s unique product code, I was able to search through
the database and record the number of recalls by level of recall (Class I-III, with Class I being
the highest risk recall and Class III the lowest risk recall; this study will only examine Class I
and Class II recalls).
Public Comments
For public comments, I was able to pull them by searching each device type’s
reclassification order / rule using its docket numbers into regulations.gov. After comments were
found, they were sorted into categories of where they came from: patient, patient advocacy
organization (PAO), health professional, health care association (HCA), academia, device
industry, government, or other organizations. For all but one device type, all comments were
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read and assessed for whether the comment supported or did not support downclassification. The
one device type that did not have all its comments read was due to the high quantity of
comments. While most other device types’ orders / rules faced a maximum of 300 comments,
one device type received 3000 comments. In order to prevent this device type’s results from
skewing further analysis, I took a random sample of 300 of its comments to characterize its
public comments.
Statistical Analysis
First, I used descriptive statistics to characterize the device type sample, to evaluate
commonalities among devices that were downclassified and devices that were not
downclassified. More specifically, we used descriptive statistics when evaluating all of the
device type base characteristics. We looked further into recall rates, before and after
reclassification along with the percentage of recalls within each class of recall risks. Similarly,
public comments were evaluated overall but also dependent on whether the device was later
downclassified.
Second, we then used Fisher exact tests to assess whether any of these factors could
predict downclassifications by testing bivariate associations between each of the device type
characteristics and whether it was downclassified. Analyses were all performed using Stata
version 16.0.
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RESULTS
Table 1. Individual device types reviewed under the 515 Program Initiative
Year
2011

Device
Topical Oxygen
Female Condom
Pacemaker Repair or
Replacement Material

2012

2013

2014

2015

2016

Therapeutic Area
General & Plastic
Surgery
Obstetrics /
Gynecology
Cardiovascular

Ventricular Bypass Device
Implantable Pacemaker Pulse
Generator

Cardiovascular

Pacemaker Programmers

Cardiovascular

Cardiovascular Permanent
Pacemaker Electrode

Cardiovascular

Temporary Mandibular
Condyle Reconstruction Plate
Intra-aortic Balloon and
Control System
External Counter-pulsating
Devices
Sorbent Hemoperfusion
System
Endosseous Dental Implant
(Blade-form)
Implanted Blood Access
Automated External
Defibrillators

Cardiovascular

Downclassified

Split reclassified

x
x
x
x
x
x
x
x

Dental

x

Cardiovascular

x

Cardiovascular
Gastroenterology /
Urology

x
x

Dental
Gastroenterology /
Urology
Cardiovascular

Nonroller-type Blood Pump

Cardiovascular

Shortwave Therapy
Extracorporeal Circuit &
Assessories For Long-term
Respiratory/Cardiopulmonary
Failure (ECMO)

Physical Medicine

Hip joint metal/metal semiconstrained, with an
uncemented and cemented
acetabular component,
prosthesis
External Pacemaker Pulse
Generator (EPPG)
External Cardiac Compressor
(ECC)

Stayed
Class III

x
x
x
x
x

Cardiovascular

x
Orthopedic
Orthopedic
Cardiovascular
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x
x

2018
2019

Thoracolumbosacral Pedicle
Screw Systems and SemiRigid Systems

Orthopedic

Electroconvulsive Therapy
Devices

Neurology

Cranial Electrotherapy
Stimulator

Neurology

x
x
x

Table 2. General characteristics of device types reviewed under the 515 Program Initiative
No. (%)
Downclassified? p-values*
Therapeutic area
15
0.531
Cardiovascular
12 (52.2%)
6
0.193
Dental
2 (8.7%)
2
0.526
Gastroenterology / Urology
2 (8.7%)
2
0.526
General & Plastic Surgery
1 (4.3%)
1
1.000
Neurology
2 (8.7%)
2
0.526
Obstetrics / Gynecology
1 (4.3%)
0
0.348
Orthopedic
2 (8.7%)
1
1.000
Physical Medicine
1 (4.3%)
1
1.000
Implantable
Yes
8 (34.8%)
4
0.371
No
15 (65.2%)
11
Life-sustaining
Yes
2 (8.7%)
2
0.526
No
21 (91.3%)
13
Reclassification Mechanism
Final rule
16 (69.6%)
14
0.002
Final order
7 (30.4%)
1
PAS / 522 Requirements
Yes
1 (4.3%)
0
0.348
No
22 (95.7%)
15
Prior 510(k)s
Yes
21 (91.3%)
15
0.111
No
2 (8.7%)
0
Devices out after reclassification
Yes
15 (65.2%)
11
0.371
No
8 (34.8%)
4
Advisory Committee Decision
Agrees with final classification
22 (95.7%)
14
0.000
Disagrees with final
1 (4.3%)
classification
1
* p-values were derived from Fisher Exact tests.
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Of the 23 classification rules and orders, 8 called for the devices to remain Class III
device types, 9 called for downclassifications to Class II, and 6 called for split-reclassifications
(Table 1). Across the device types, 8 (34.89%) are implantable and only 2 (8.7%) are lifesustaining (Table 2). The most prevalent therapeutic area is cardiovascular, as it made up 12 of
the 23 (52.1%) device types. Overall, 21 (91.3%) device types had at least one device approved
through the 510(k) pathway and 15 (65.2%) have produced new devices since the final
classification announcement (Table 2). Only one device (4.3%) required either PAS or 522
requirements. Additionally, 14 of the 15 devices that were ultimately downclassified faced
advisory committee decisions that supported this classification.
Table 3. Recall history and public comments for 515 device types.
No. (%)
Downclassified?
Recalls
10
Class I
8 (34.8%)
4
Class II
15 (65.2%)
10
Public Comments
13
Academia
7 (30.4%)
5
If device received comments
7 (41.2%)
Device Industry
7 (30.4%)
6
If device received comments
7 (41.2%)
Government
1 (4.4%)
0
If device received comments
1 (5.9%)
7 (30.4%)
Health Care Associations
5
If device received comments
7 (41.2%)
Health professionals
8 (34.8%)
7
If device received comments
8 (47.1%)
Other organizations
3 (13.0%)
2
If device received comments
3 (17.7%)
Patients
5 (21.7%)
4
If device received comments
5 (29.4%)
Patient Advocacy Organizations
16 (69.6%)
12
If device received comments
16 (94.1%)
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p-values
1.000
0.371
1.000
0.131
1.000
0.345
0.348
1.000
0.176
1.000
0.621
0.182

Recalls
Overall, 15 (65.2%) device types have had at least one device face either a Class I or
Class II recall. For Class I, 8 devices faced at least one Class I recall, that is 34.7% of all devices
and 53.3% of devices that faced at least one recall. For Class II recalls, 15 devices faced at least
one Class II recall, that is 65.2% of all devices and 100% of devices that faced at least one
recall. Additionally, all 8 devices that faced at least one Class I recall also experienced at least
one Class II recall.
Public Comment
17 (73.9%) of device types received at least one public comment. Out of the 8 potential
sources for comments, PAOs had the greatest turnout rate, as they commented on classification
announcements of 16 (94.1%) devices out of the 17 that received at least one comment. The next
highest turnout was in health professionals, by commenting on 8 (47.1%) devices. Then HCAs,
academics, and the device industry each commented on 7 devices (41.18%). In similar ranges,
patients responded to 5 devices (29.4%) and other non-specified organizations commented on 3
devices (17.7%). Lastly, government entities only commented on 1 device (5.9%). Despite most
devices receiving at least one public comment, none of these public comment categories were
associated with the final device classification.
Predictors of Downclassification
Most device type characteristics were not significantly associated with final classification
decision. Notably, none of the therapeutic areas were associated with downclassifications (P =
0.531) (Table 2). Similarly, whether or not a device type received public comments, both in
general and across types of submissions, was not associated with downclassifications (P = 0.131)
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(Table 3). Recalls were found not to be associated with downclassifications (P = 0.250; P =
0.448) (Table 3).
But, there were two characteristics that were significantly associated with
downclassifications. All final device classifications directly aligned with the advisory committee
decisions, as there is a statistically significant association between these (P = 0.000) (Table 2).
Similarly, most devices that were classified through final rule stayed Class III, whereas most
devices classified through final order were down classified. The classification mechanism was
also associated with final device classifications (P = 0.000) (Table 2).

DISCUSSION
This evaluation of the 515 Program Initiative, done by delving into the device
reclassifications instigated through this procedure, demonstrates that reclassifications (and, more
specifically, downclassifications) are largely device-specific but are decided with heavy
influence from key stakeholders and administrative procedures. All 23 device types that were reassessed through this initiative were assessed on a variety of characteristics and were found to be
largely heterogeneous but some associations were found between these characteristics and final
classification. Determining these significant associations can lend itself to elucidating important
factors to the FDA’s decision-making process, which can both positively and negatively impact
patient safety.
Most device characteristics were not significantly associated with the final classification
decisions but two factors did show potential for being predictors. First, the advisory committee
opinion seemed to play a huge role in whether the device type was down classified. For all
device types, all advisory committee decisions directly aligned with the final decision to
downclassify, except for one device where the FDA specifically indicated the advisory

14

committee decision was made prior to significant evidence that changed the science base for
reclassification. This alignment signifies the key role of advisory committees to not only device
classifications but also in FDA decision-making as a whole, as various statutes regarding the
FDA requires the FDA to confer with advisory committees before proceeding. This finding is
consistent with previous studies evaluating the relationship advisory committee decisions and
FDA actions, which confirms that these committee opinions play a large role in FDA
decisions.viii As this influence is large, this suggests that the FDA may need to more effectively
consider and evaluate who ends up on an advisory committee, considering the impact advisory
committees have.
Second, whether the device type was downclassified through a final rule or final order
playing a role could be telling over the role of regulatory burden on decision-making. The results
indicated that more device types that were classified through a final rule were not downclassified
than device types classified through a final rule. Given that a final order is easier to pass than a
final rule, this indicates that the amount of regulatory scrutiny placed on a device undergoing
evaluation plays a role in whether the device gets downclassified or not. This falls in line with
previous literature, suggesting that the FDA is overloaded and may take steps to reduce the
regulatory burden across the board, in order to increase innovation but potentially at the expense
of safety.ix
Of note, there were two characteristics that were not significantly associated with the
final classification that could signify greater problems within the reclassification process: recalls
and public comments. Recalls did not show to be significantly associated with the final
classification. This is an area for concern because the FDA has come under criticism for not
appropriately handling devices that cause many recalls. As it stands, only a few device types
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cause the majority of recalls. Most of those device types tend to be in the cardiovascular
therapeutic area; a decent amount of the device types evaluated under the 515 Program Initiative
were cardiovascular and were downclassified, despite evidence of recalls. This is particularly of
interest because the literature has found that most recalls resulting from cardiovascular medical
devices and, more specifically, a small subset of cardiovascular devices, a few of which were
downclassified through this initiative.x This brings into question how much the FDA may be
evaluating the risks of these devices based on real-world evidence.
Public comments also did not play a distinct role in whether the devices were
downclassified. Across the spectrum of where the comments came from, none were shown to be
significantly associated with the final risk specification. This is consistent with the current
literature that regulatory agencies largely listen to comments to enhance their current position
rather than alter their decisions dependent on the comments. xi Although this is a required
component to the regulatory process and the FDA does address significant comments in the final
rule and order write-ups, this assessment shows that the public comment portion may serve as an
administrative specification rather than playing a role in the FDA’s decision-making process.
Additionally, through the characterization of these medical devices, we see that the
remaining devices that needed to be evaluated under the 515 Program Initiative are quite diverse.
There were not too many similarities across the general characteristics, other than that most were
cardiovascular and not life-sustaining, although these characteristics also make up the majority
of devices currently on the market. This could again suggest that the FDA must take a
considerable amount of time in order to look at these device classification decisions, which may
cause the FDA to proceed on the path that leads to the least future regulatory burdens.
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Moving forward, these results could provide insight on the FDA’s decision-making,
especially as it relates to device risk reclassifications, since, at the same time as the creation of
the 515 Program Initiative, the FDA also launched changes to Section 513, which made it also
easier from a regulatory perspective to reclassify de novo devices. That being said, now that the
FDA has finished classifying devices under the 515 Program Initiative, it could have more time
to dedicate to the de novo reclassification process. But these findings should be considered as the
FDA approaches reclassifications overall because this is a key power that the FDA has in order
to protect the public, in line with its core mission.
This analysis has several limitations worth consideration. First, when assessing public
comments, for many of the devices, at least a few comments were blocked from review by
regulations.gov or the FDA itself. Therefore, not all comments could be viewed. With some
devices only receiving a few comments with half of those blocked, this could have skewed the
results. Additionally, one device received over 1000 comments. To ensure that this device’s
comments would not mask the results of other devices that received fewer comments, a sample
of 300 comments were taken for analysis. This could additionally be not as representative of
these comments as assessing all comments from this device type. Second, as there were only 26
devices that needed to be reevaluated under the 515 Program Initiative, the sample size was very
small. It is difficult to accurately say these results are not simply random. Third, the 515 Program
Initiative is special in two respects: it began to tackle a specific problem and that these devices
are inherently unique. Congress created this to assist the FDA in their long-term effort to
reclassify these devices. The incentives to make this a speedy process may not apply to current
or future reclassification efforts by the FDA. These preamendment devices are very different
from devices that now come up as de novo devices that are seeking reclassification.

17

All in all, these findings suggest that the FDA prioritizes certain key players, such as
experts within advisory committees, during their decision-making process and that regulatory
burdens could both help and hinder the FDA’s mission to ensure safety and effectiveness.
Although the 515 Program Initiative is special in its own right, it gives us much to think about
for the future of regulatory bandwidths, how the FDA may choose to review devices, and, most
importantly, how FDA decisions may impact patient safety.
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